medical device investing Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR